Abstract
Glycated haemoglobin, or HbA1c, is the main biomarker used to assess long-term glycaemic control in individuals with diabetes, and it correlates with the development of complications. The aim of this article is to provide an overview of HbA1c to understand its role inthe treatment of individuals living withdiabetes. Topics discussed include recommended treatment targets, methods of measurement, causes of measurement inaccuracy and alternative means available to assess glycaemic control. HbA1c should not be interpreted in isolation; the measurement accuracy and other parameters, including treatment goals and comorbidities, need to be considered.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
